An immunohistochemical analysis of the neuroprotective effects of memantine, hyperbaric oxygen therapy, and brimonidine after acute ischemia reperfusion injury

Molecular Vision

Volumn 17, Issue , 2011, Pages 1024-1033

  Yig̈it, Ulviye ^a   Erdenöz, Serkan ^b   Uslu, Ünal ^c   Oba, Ersin ^d   Cumbul, Alev ^c   Çag̈atay, Halil ^e   Aktaş, Şamil ^f   Eskicog̈lu, Emiray ^g  

^a Dr Sadi Konuk Training and Research Hospital   (Turkey)

^b Akyazi State Hospital   (Turkey)

^c YEDITEPE UNIVERSITY   (Turkey)

^d SISLI ETFAL TRAINING AND RESEARCH HOSPITAL   (Turkey)

^e MERSIN STATE HOSPITAL   (Turkey)

^f ISTANBUL UNIVERSITY   (Turkey)

^g TRAKYA UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; GLUTARALDEHYDE; MEMANTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANNULATION; CONTROLLED STUDY; DRUG EFFICACY; ENUCLEATION; HISTOPATHOLOGY; HYPERBARIC OXYGEN; IMMUNOHISTOCHEMISTRY; INTRAOCULAR HYPERTENSION; NEUROPROTECTION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; RETINA GANGLION CELL; RETINA ISCHEMIA; THERAPY EFFECT; TREATMENT DURATION;

ANIMALS; CELL COUNT; DISEASE MODELS, ANIMAL; HYPERBARIC OXYGENATION; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRAVENOUS; MEMANTINE; NEUROPROTECTIVE AGENTS; OPHTHALMIC SOLUTIONS; QUINOXALINES; RATS; RATS, WISTAR; REPERFUSION INJURY; RETINA; RETINAL GANGLION CELLS;

EID: 79955578772     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Osborne NN, Casson RJ, Wood JP, Chidlow G, Graham M, Melena J. Retinal ischemia: Mechanisms of damage and potential therapeutic strategies. Prog Retin Eye Res 2004; 23:91-147. [PMID: 14766318]
2. Bonne C, Muller A, Villain M. Free radicals in retinal ischemia. Gen Pharmacol 1998; 30:275-280. [PMID: 9510074]
3. Beiran I, Goldenberg I, Adir Y, Tamir A, Shupak A, Miller B. Early hyperbaric oxygen therapy for retinal artery occlusion. Eur J Ophthalmol 2001; 11:345-350. [PMID: 11820305]
4. Weinberger AW, Siekmann UP, Wolf S, Rossaint R, Kirchhof B, Schrage NF. Treatment of acute central retinal artery occlusion (CRAO) by hyperbaric oxygenation therapy (HBO) -Pilot study with 21 patients. Klin Monatsbl Augenheilkd 2002; 219:728-734. [PMID: 12447717]
5. Li HK, Dejean BJ, Tang RA. Reversal of visual loss with hyperbaric oxygen treatment in a patient with Susac syndrome. Ophthalmology 1996; 103:2091-2098. [PMID:9003343]
6. Aisenbrey S, Krott R, Heller R, Krauss D, Rössler G, Heimann K. Hyperbaric oxygen therapy in retinal artery occlusion. Ophthalmologe 2000; 97:461-467. [PMID: 10959180]
7. Kiryu J, Ogura Y. Hyperbaric oxygen treatment for macular edema in retinal vein occlusion: relation to severity of retinal leakage. Ophthalmologica 1996; 210:168-170. [PMID:8738462]
8. Krott R, Heller R, Aisenbrey S, Bartz-Schmidt KU. Adjunctive hyperbaric oxygenation in macular edema of vascular origin. Undersea Hyperb Med 2000; 27:195-204. [PMID: 11419360]
9. Butler FK Jr. Diving and hyperbaric ophthalmology. Surv Ophthalmol 1995; 39:347-366. [PMID: 7604359]
10. Blair NP, Baker DS, Rhode JP, Solomon M. Vitreoperfusion. A new approach to ocular ischemia. Arch Ophthalmol 1989; 107:417-423. [PMID: 2923567]
11. Henkind P, Chambers JK. Arterial occlusive disease of the retina. In, Duane TD, editor. Clinical ophthalmology; Volume 14. Philadelphia: Harper and Row; 1986. p. 1-14.
12. Brown GC. Retinal arterial obstructive disease. In, Schachat AP, Murphy RB, Patz A, editors. Retina; Volume 2. St.Louis: CV Mosby Company; 1989. p. 403-419.
13. Kanski JJ. Clinical ophthalmology. London: Butterworths and Co. publishers; 1989. p. 324-328.
14. Brown GC. Arterial obstructive disease and the eye. In, Stamper RL, editor. Ophthalmology Clinics of North America. Philadelphia: WB Saunders Company; 1990. p. 33:373-391.
15. Lapchak PA. Memantine, an uncompetitive low affinity NMDA open-channel antagonist improves clinical rating scores in a multiple infarct embolic stroke model in rabbits. Brain Res 2006; 1088:141-147. [PMID: 16626666]
16. Arundine M, Tymianski M. Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004; 61:657-668. [PMID: 15052409]
17. Nickells RW. Retinal ganglion cell death in glaucoma: the how, the why and the maybe. J Glaucoma 1996; 5:345-356. [PMID:8897235]
18. Le DA, Lipton SA. Potential and current use of N-methyldaspartate (NMDA) receptor antagonists in diseases of aging. Drugs Aging 2001; 18:717-724. [PMID: 11735619]
19. Parsons CG, Danysz W, Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist- a review of preclinical data. Neuropharmacology 1999; 38:735-767. [PMID: 10465680]
20. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol 1999; 9:S17-S21. [PMID: 10230601]
21. Vidal-Sanz M, Lafuente MP, Mayor S, Miralles de Imperial J, Villegas-Perez MP. Retinal ganglion cell death induced by retinal ischemia: neuroprotective effects of two alpha-2 agonists. Surv Ophthalmol 2001; 45:261-267.
22. Lai RK, Chun T, Hasson D, Lee S, Mehrbod F, Wheeler L. Alpha-2 adrenoreceptor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci 2002; 19:175-185. [PMID: 12385629]
23. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha 2 adrenerjic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008; 49:4515-4522. [PMID: 18566471]
24. Beach TG, Tago H, Nagai T. Perfusion-fixation of the human brain for immunohistochemistry: comparison with immersion-fixation. J Neurosci Methods 1987; 19:183-92. [PMID: 2437408]
25. Miller DC. Use of perfusion fixation for improved neuropathologic examination. arch Pathol Lab Med 1998; 122:949. [PMID: 9822120]
26. West MJ, Slomianka L, Gundersen HJ. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 1991; 231:482-497. [PMID: 1793176]
27. West MJ, Ostergaard K, Andreassen OA, Finsen B. Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical fractionator method. J Comp Neurol 1996; 370:11-22. [PMID: 8797153]
28. Chen ST, Sultzer DL, Hinkin CH, Mahler ME, Cummings JL. Executive dysfunction in Alzheimer's disease: association with neuropsychiatric symptoms and functional impairment. J Neuropsychiatry Clin Neurosci 1998; 10:426-432. [PMID:9813788]
29. Stieg PE, Sathi S, Warach S, Le DA, Lipton SA. Neuroprotection by the NMDA receptor-associated openchannel blocker memantine in a photothrombotic model of cerebral focal ischemia in neonatal rat. Eur J Pharmacol 1999; 375:115-120. [PMID: 10443569]
30. Vidal-Sanz M, Lafuente MP, Sobrado-Calvo P. Death and neuroprotection of retinal ganglion cells after different types of injury. Neurotox Res 2000; 2:215-27. [PMID: 16787842]
31. Osborne NN, Cazevieielle C, Pergande G, Wood JPM. Induction of apoptosis in cultured human retina pigment epithelial cells is counteracted by flupirtine. Invest Ophthalmol Vis Sci 1997; 38:1390-1400. [PMID: 9191602]
32. Lam TT, Fu J, Hrynewycz M, Tso MO. The effect of aurintricarboxylicacid, an endonuclease inhibitor, on ischemia/reperfusion damage in rat retina. J Ocul Pharmacol Ther 1995; 11:253-259. [PMID: 8590257]
33. Kim TW, Kim DM, Park KH, Kim H. Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia. Korean J Ophthalmol 2002; 16:1-7. [PMID: 12162511]
34. Prasanna G, Krishnamoorthy R, Clark AF, Wordinger RJ, Yorio T. Human optic nerve head astrocytes as a target for endothelin-1. Invest Ophthalmol Vis Sci 2002; 43:2704-2713. [PMID: 12147606]
35. Rao VL, Dogan A, Todd KG, Bowen KK, Dempsey RJ. Neuroprotection by memantine, a non-competitive NMDA receptor antagonist after traumatic brain injury in rats. Brain Res 2001; 911:96-100. [PMID: 11489449]
36. Osborne NN, Herrera AJ. The effect of experimental ischaemia and excitatory amino acid agonists on the GABA and serotonin immunoreactivities in the rabbit retina. Neuroscience 1994; 4:1071-1081.
37. Lagrèze WA, Knörle R, Bach M, Feuerstein TJ. Memantine is neuroprotective in a rat model of pressure-induced retinal ischemia. Invest Ophthalmol Vis Sci 1998; 39:1063-1066. [PMID: 9579489]
38. WoldeMussie E, Yoles E, Schwartz M, Ruiz G, Wheeler LA. Neuroprotective effect of memantine in different retinal injury models in rats. J Glaucoma 2002; 11:474-480. [PMID:12483089]
39. Lagrèze WA, Otto T, Feuerstein TJ. Neuroprotection in ischemia of the retina in an animal model. Ophthalmologe 1999; 96:370-374. [PMID: 10429494]
40. Okamoto N, Nishimura Y, Goami K, Harino S. Effect of hyperbaric oxygen on ophthalmic artery blood velocity in patients with diabetic neuropathy. Jpn J Ophthalmol 1998; 42:406-10. [PMID:9822973]
41. Oguz H, Sobaci G. The use of hyperbaric oxygen therapy in ophthalmology. Surv Ophthalmol 2008; 2:112-120.
42. Yoles E, Wheeler L, Schwartz M. Alpha-2-adrenoreceptor agonists are neuroprotective in a rat model of optic nevre degeneration. Invest Ophthalmol Vis Sci 1999; 40:65-73. [PMID: 9888428]
43. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser induced chronic ocular hypertension. Invest Ophthalmol Vis Sci 2001; 42:2849-2855. [PMID: 11687528]
44. Vidal-Sanz M, Lafuente MP, Mayor-Torrglosa S, Aguilera ME, Mirrales de Imperial J, Villegas-Perez MP. Brimonidine's neuroprotective effects against transient ischaemia induced retinal ganglion cell death. Eur J Ophthalmol 2001; 11:S36-S40. [PMID: 11592529]
45. Wen R, Cheng T, Li Y, Cao W, Steinberg R. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci 1996; 16:5986-5992. [PMID: 8815881]
46. Aktas Z, Gurelik G, Akyurek N, Onol M, Hasanreisoglu B. Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin-1-induced optic nerve ischaemia model. Clin Exp Ophthalmol 2007; 35:527-534.
47. Achheampong AA, Shackleton M, Tang-Liu DD. Comperative ocular pharmacokinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos 1995; 23:708-712. [PMID: 7587958]
48. Gao H, Qiao X, Cantor LB. WuDunn D. Up-regulation of brainderived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002; 120:797-803. [PMID: 12049586]